Wedbush Lifts PT on Sana Biotechnology (SANA) to $7 From $6

Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the best stocks under $5 with huge upside potential. Wedbush lifted the price target on Sana Biotechnology, Inc. (NASDAQ:SANA) to $7 from $6 on April 14, reaffirming an Outperform rating on the shares. The firm stated that the company announced a collaboration with the Mayo Clinic to develop protocols and processes for type 1 diabetes candidate SC451, with a concurrent investment of up to $50 million. Wedbush added that The Mayo Clinic will initially purchase 7.5 million shares for gross proceeds of $25 million, and will hold an option to purchase an additional 7.5 million shares before August 31, 2026. Sana Biotechnology, Inc. (NASDAQ:SANA) expects the cash runway to extend into 2027 based on the initial $25 million investment, according to the firm.

Sana Biotechnology, Inc. (NASDAQ:SANA) announced its collaboration with Mayo Clinic across multiple areas on April 13, aimed at accelerating the development of and access to potentially curative therapies for patients with type 1 diabetes.

Sana Biotechnology (NASDAQ:SANA) is a biotechnology company that specializes in using engineered cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders.

While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.

View Comments